Dignan,
This is on your list as Phase I but there is a lot of coverage in the media today.
Ian
http://c.moreover.com/click/here.pl?j625859514&w=464753
MLN0415
Another article on the same story. At least a large drugs company is also involved which should help fund the trials. Many of the drugs in trial e.g. Rituxan (and this one) are targetting both MS and RA. I wonder if any poor soul has got both?
Ian
Millennium launches test for inflammation treatment
Millennium Pharmaceuticals Inc. has launched an early-stage human clinical trial to test a new treatment for inflammation.
The Cambridge, Mass. based company announced Wednesday that it had launched the Phase I trial of MLN0415, a molecule Millennium's scientists have discovered that apparently targets a key pathway involved in inflammation. The thought is that the drug could help prevent inflammation or delay the progression of an inflammation-related disease.
The trial will involve up to 72 volunteers and assess safety and tolerability of the drug. If successful, the drug will move into Phase II trials involving actual sick patients and then a larger pool of sick patients in Phase III trials before it is submitted for federal marketing approval.
Millennium is developing the drug with global pharmaceutical company Sanofi-Aventis; the two formed an alliance to develop and market new drugs focused on inflammatory diseases such as rheumatoid arthritis and multiple sclerosis.
Source: Yahoo Finance Copyright © 2006 Yahoo! Inc. All rights reserved
Ian
Millennium launches test for inflammation treatment
Millennium Pharmaceuticals Inc. has launched an early-stage human clinical trial to test a new treatment for inflammation.
The Cambridge, Mass. based company announced Wednesday that it had launched the Phase I trial of MLN0415, a molecule Millennium's scientists have discovered that apparently targets a key pathway involved in inflammation. The thought is that the drug could help prevent inflammation or delay the progression of an inflammation-related disease.
The trial will involve up to 72 volunteers and assess safety and tolerability of the drug. If successful, the drug will move into Phase II trials involving actual sick patients and then a larger pool of sick patients in Phase III trials before it is submitted for federal marketing approval.
Millennium is developing the drug with global pharmaceutical company Sanofi-Aventis; the two formed an alliance to develop and market new drugs focused on inflammatory diseases such as rheumatoid arthritis and multiple sclerosis.
Source: Yahoo Finance Copyright © 2006 Yahoo! Inc. All rights reserved